A Dual‐Targeting Liposome Enhances Triple‐Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation (Small 40/2023)
Source abstract
Abstract
Triple-Negative Breast Cancer Chemoimmunotherapy In article number 2302834, Kaipei Luo, Xiaofang Li, and co-workers develop a LyP-1 and chondroitin sulfate dual-modified liposome co-loading paclitaxel and cryptotanshinone. The liposome enhances cellular uptake via p32/CD44 dual receptor-mediated endocytosis, and achieves potent triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Chemokine receptors and signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu 611137 China
Innovative Institute of Chinese Medicine and Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu 611137 China
Personalized Drug Therapy Key Laboratory of Sichuan Province Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China Chengdu 610072 China
References
Reference metadata was not supplied for this record.